Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>HGH Fragment 176-191
Minimal evidenceGH / growth factors

HGH Fragment 176-191

A synthetic fragment of the growth hormone molecule studied for isolated fat-metabolism effects in animal work. Human evidence is essentially absent.

CompoundHGH Fragment 176-191
CategoryLipolytic HGH fragment
ClassGrowth Hormone and Growth Factors
Evidence tierMinimal evidence
WADA statusNot individually listed; verify current status if subject to testing
Sold on this siteNo — this is a reference database

Overview

HGH Fragment 176-191 is catalogued here as a lipolytic hgh fragment and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

A synthetic fragment of the growth hormone molecule studied for isolated fat-metabolism effects in animal work. Human evidence is essentially absent.

Mechanism of Action

The 176-191 region of GH is associated with lipolytic activity in early pharmacology research; the fragment is hypothesized to retain fat-mobilizing effects without growth-promoting or diabetogenic actions.

Research and Evidence

A handful of animal studies from decades ago; no controlled human trials. The related modified peptide AOD-9604 failed in obesity trials (see its entry).

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

No human safety database; unregulated product quality is the immediate practical risk.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of HGH Fragment 176-191?

HGH Fragment 176-191 is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

Is HGH Fragment 176-191 an approved medicine?

No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for HGH Fragment 176-191?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — search for HGH fragment studies. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement